Fig. 3.

The proliferation of HepG2 and Li-7 cells was inhibited by hGC33, null-NP, and hGC33-null-NP. a Cell proliferation test was performed on GPC3-positive HepG2 cells treated with hGC33, null-NP or hGC33-null-NP; b cell proliferation tests were conducted on GPC3 negative Li-7 cells treated with hGC33, null-NP, and hGC33-null-NP. The cells were incubated with 0–2.5 μM hGC33, null-NP, or hGC33-null-NP for 1 day. The proliferation of the cells was measured with MTT method and standardized as untreated cells. All values represent the mean ± SD. Compared with the control group (0 μM) without antibody treatment, *P < 0.01; c the representative results of response of HepG2 to hGC33, null-NP, and hGC33-null-NP in hGC33 treatment (1.0 μM)